2019
DOI: 10.1016/j.heares.2019.07.003
|View full text |Cite
|
Sign up to set email alerts
|

Early phase trials of novel hearing therapeutics: Avenues and opportunities

Abstract: Novel hearing therapeutics are rapidly progressing along the innovation pathway and into the clinical trial domain. Because these trials are new to the hearing community, they come with challenges in terms of trial design, regulation and delivery. In this paper, we address the key scientific and operational issues and outline the opportunities for interdisciplinary and international collaboration these trials offer. Vital to the future successful implementation of these therapeutics is to evaluate their potent… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
14
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 18 publications
(14 citation statements)
references
References 164 publications
(169 reference statements)
0
14
0
Order By: Relevance
“…A number of pharmacologic interventions to help protect the ear from over-exposure to loud noise appear to be on the horizon, but nothing is FDA-approved yet [248,249]. Hearing aids are helpful but do not restore natural hearing ability, and there is currently no cure for tinnitus or hyperacusis [250], nor for bringing back lost cochlear hair cells and nerve fibers [251][252][253]. NIHL can precipitate depression, social withdrawal, and cognitive decline [254][255][256][257][258][259][260], and mild, moderate, and severe hearing loss increases the risk of dementia by 2-, 3-and 5-fold, respectively [261][262][263].…”
Section: Preventing Noise-induced Hearing Lossmentioning
confidence: 99%
“…A number of pharmacologic interventions to help protect the ear from over-exposure to loud noise appear to be on the horizon, but nothing is FDA-approved yet [248,249]. Hearing aids are helpful but do not restore natural hearing ability, and there is currently no cure for tinnitus or hyperacusis [250], nor for bringing back lost cochlear hair cells and nerve fibers [251][252][253]. NIHL can precipitate depression, social withdrawal, and cognitive decline [254][255][256][257][258][259][260], and mild, moderate, and severe hearing loss increases the risk of dementia by 2-, 3-and 5-fold, respectively [261][262][263].…”
Section: Preventing Noise-induced Hearing Lossmentioning
confidence: 99%
“…In order to prevent SGC degeneration, many studies have investigated the effect of exogenous administration of neurotrophins, in particular the naturally occurring neurotrophin brain-derived neurotrophic factor (BDNF), which significantly enhances SGC survival in deafened guinea pigs (e.g., [1,[12][13][14][15][16][17][18][19][20]), cats [21,22] and rats [23]. These animal studies pave the way for possible human applications to benefit CI users [24,25], or as a potential treatment to counteract synaptopathy [26,27]. Importantly, treatment of exogenous BDNF does not only have a positive effect on structural survival of the auditory nerve; its responsiveness to electric current pulses, as provided by a CI, is also significantly improved [14,19,21,28].…”
Section: Introductionmentioning
confidence: 99%
“…Hearing restoration strategies currently under preclinical and early clinical investigation include gene therapy approaches and different modalities to induce tissue repair (reviewed in References 48‐51). The first, focus on gene correction, through gene or base editing, 52‐54 or gene replacement, 55‐58 to modify or bypass genetic defects.…”
Section: Introductionmentioning
confidence: 99%